ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Core Insights - ArriVent BioPharma has entered into an exclusive license agreement with Lepu Biopharma for MRG007, an antibody-drug conjugate targeting gastrointestinal cancers, granting ArriVent rights to develop and commercialize MRG007 outside Greater China [1][3] - MRG007 is considered a potential best-in-class ADC for GI malignancies, with plans for the first IND submission in the first half of 2025, focusing on colorectal cancer, pancreatic cancer, and other GI cancers [2][6] - The agreement includes a one-time upfront payment and milestone payments totaling $47 million, with potential additional payments of up to $1.16 billion based on development and sales milestones [3] Company Overview - ArriVent is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer, leveraging deep drug development experience to advance its pipeline, including next-generation ADCs [4] - Lepu Biopharma is an innovation-driven company specializing in oncology therapeutics, particularly ADCs, with a strong focus on R&D and commercialization capabilities [5]